Work

Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC).

Year: 2009

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs-09-5099

Authors: P. LoRusso, S. Girish, H. Burris, M. Beeram, S. Vukelja, S. Modi, J. Yi, B. Wang, O. Saad, M. Gupta

Institutions: The Barbara Ann Karmanos Cancer Institute, Sarah Cannon, Memorial Sloan Kettering Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2080710909

Cites:

Cited by: 3

Related to: 10